Verana Health Expands Clinical Trial Tools with Real World Data Integration
Verana Health announced in a press release new features for its Site Explorer and Verana Trial Connect applications to improve site selection and patient enrollment in clinical trials. The tools now provide full process visibility for sponsors and contract research organizations through real time dashboards that display deidentified screening activity and site performance.
The Site Explorer platform helps sponsors locate medical practices with patient populations that match their study criteria and shows how inclusion and exclusion rules affect eligible trial populations. Verana Trial Connect uses data from electronic health records to identify potential participants and automate eligibility checks, reducing manual review and accelerating the prescreening process.
Verana Health’s data access comes through partnerships with the American Academy of Ophthalmology IRIS Registry and the American Urological Association Quality Registry. These collaborations give the company deidentified health records for more than 95 million patients across over 3,200 practices, refreshed regularly to ensure current insights for trial planning and execution.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
AstraZeneca and Oracle Partner on AI for Clinical Trials
Orakl Oncology Raises $34 Million to Predict Cancer Drug Response With AI
Illumina Adds Three Research Tools to BioInsight Platform
Atlas Bio raises $12.5 million for virtual drug trials
Alethios Adds Decentralized Health Research Data Suite
Daily AI Brief: the AI news that matters, in your inbox.